For the remainder of this study, we focused solely on the p.D160N mutation of the SIVA apoptosis inducing factor (SIVA-D160N), as deep deletion of SIVA was reported in 12% (36/301) of metastatic breast cancers [36], and SIVA downregulation promoted breast cancer cell aggressiveness both in vitro and in vivo [21]. This evidence concerns the gene SIVA1 and breast carcinoma.